Slide 1: Creating a World Class Platform
Creating a World Class Platform Investor Presentation April 2025 © 2025 AtriCure, Inc. All rights reserved.
Slide 2: Forward Looking Statements and Non-GAAP Financial Measures
Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. Forward-looking stat
Slide 3: Our Vision
Our Vision Strong Portfolio Existing products and solutions and continuous innovation driving consistent growth We are passionately Large and Growing Markets focused on Addressing underserved and growing patient populations, representing a $10B opportunity healing the lives of those affected Global
Slide 4: Strategic Focus
Strategic Focus Profitable Expansion Growth Clinical Innovation Science Developing Strong history of addressable markets revenue growth and Continuous Differentiated clinical and expanding acceleration from improvement, trials with superior patient impact multiple catalysts with increasing pipeline
Slide 5: Afib: A Serious Problem
Afib: A Serious Problem Afib affects more than 59 million people worldwide. It is estimated that 45% have suffered more than a year from Afib. 5x Higher Risk of >5x Higher Risk of Stroke Heart Failure 46% Greater Risk of >3x Higher Risk of Mortality Dementia © 2025 AtriCure, Inc. All rights reserved
Slide 6: A Persistent Pain Problem
A Persistent Pain Problem Pain after surgery slows recovery. Pain after surgery increases healthcare costs. Pain after surgery reduces quality of life. 30%-50% of patients report persistent pain lasting months to years post-surgery 1 in 7 thoracotomy patients 1 in 11 minimally invasive develop an op
Slide 7: AtriCure Patient Profile
AtriCure Patient Profile Differentiated Focus: Creating Standards of Care for Patients with Advanced Afib and Managing Post-Operative Pain Afib Pain Management Structural Heart Issue No Structural Issue Thoracic Surgery Surgery required (Valve, CABG) Afib is primary concern Intercostal nerve pain Af
Slide 8: Evolution of Our Global Market Opportunity
Evolution of Our Global Market Opportunity $5B+ Current Global Opportunity $1B in 2010 Pain Management Ablation Thoracic Procedures Hybrid Cardiac Therapy Surgery MIS Ablation + Open Ablation + LAAM LAAM Cardiac Surgery Standalone Treatment Concomitant for Long-Standing Treatment Pre-Op Afib Open Ab
Slide 9: Opportunity Will Grow to More Than $10B by 2030!
Opportunity Will Grow to More Than $10B by 2030! $10B+ Leading with innovation, clinical science and awareness Global Opportunity to establish and grow our markets Pain Pain Pain Management Ablation Management Management Ablation Ablation Extremities + Thoracic Procedures Hybrid Therapy Sternotomy P
Slide 10: Innovation and Clinical Milestones
Innovation and Clinical Milestones 2010+ 2015+ 2020+ • Synergy system FDA • EPi-Sense® system • EPi-Sense approved by FDA for approved for treatment of acquired treatment of long-standing persistent Afib Afib concomitant to open heart procedures • AtriClip PRO-V® • EnCompass® clamp • AtriClip® devic
Slide 11: Treatment of Afib and LAAM: Advancing Guidelines for Clinical Practice
Treatment of Afib and LAAM Advancing Guidelines for Clinical Practice Lasts beyond 7 days Lasts longer than 1 year and as long as 1 year without stopping Sources included in Appendix © 2025 AtriCure, Inc. All rights reserved. 11
Slide 12: Treatment of Afib and LAAM: Improving Access through Reimbursement
Treatment of Afib and LAAM Improving Access through Reimbursement Hospital Reimbursement MS-DRG 317 Hospital Reimbursement Epicardial Ablation + MS-DRG 212 Lasts longer than 1 year Physician Reimbursement Epicardial LAA CPT 33267, 33268, 33269 AVR + MVR + Surgical without stopping Ablation $15k - $2
Slide 13: Cardiac Surgery Ablation + LAAM
Cardiac Surgery Ablation + LAAM Established Market and Advancing Innovation in Patient Care Key Initiatives and Growth Drivers • Penetrate global market with EnCompass Approved. Isolator Synergy clamp Ablation System first medical device with FDA approval for treatment of Afib • Drive adoption of
Slide 14: Hybrid Therapy Ablation + LAAM
Hybrid Therapy Ablation + LAAM Growing Market with Unique Solutions for Advanced Afib Patients Key Initiatives and Growth Drivers >4 Million • Drive adoption of Hybrid AF Therapy with EPi-Sense / ST and AtriClip PRO devices, People estimated to have long- expanding global customer base standing pers
Slide 15: Pain Management
Pain Management Leading Market Development through Ablation Expertise Key Initiatives and Growth Drivers • Expand adoption of 2024 new product launches: cryoSPHERE+ probe and cryoSPHERE MAX probe >1 day lower ~$14k savings 26% lower opioid • Reduced freeze times by 25% (cryoSPHERE+) length of over 6
Slide 16: First Quarter 2025 Financial Highlights
First Quarter 2025 Financial Highlights Worldwide Revenue* ($M) $124.3 $123.6 Key Metrics* +13.6% Q1 2025 Q1 2024 YoY GROSS MARGIN 74.9% 74.7% OPERATING EXPENSES $98.6M $92.2M ADJUSTED EBITDA+ $8.8M $2.8M $108.9 ADJUSTED LOSS PER SHARE+ ($0.14) ($0.25) CASH & INVESTMENTS $100M $106M Q1 2024 Q4 2024
Slide 17: Financial Results and 2025 Outlook
Financial Results and 2025 Outlook $500 $450 +17% $400 +21% $350 +20% Worldwide Revenue $300 $250 2025 Guidance $200 Worldwide Revenue $150 $517 million to $527 million $100 $50 Adjusted EBITDA $- $44 million to $46 million ($ Millions) 2021 2022 2023 2024 2025** Modest Cash Flow Generation Signific
Slide 18: Distinct Opportunity for Value Creation
Distinct Opportunity for Value Creation As We Execute Our Vision for 2030 Robust, #1 Leader in organic R&D each market. pipeline. Unrivaled commitment to Broad Innovation and develop and support our Clinical Science initiatives partners and patients. across platforms. Vastly Driving underpenetrated
Slide 19: Thank You!
Thank You! © 2025 AtriCure, Inc. All rights reserved.
Slide 20: Key Products
Key Products ATRICLIP FLEX•MiniTM DEVICE ISOLATOR® SYNERGY ATRICLIP ® ENCOMPASS ® CLAMP FLEX・V ® DEVICE cryoSPHERE ® MAX PROBE cryoSPHERE ® CRYOABLATION PROBE EPI-SENSE ® DEVICE ISOLATOR® SYNERGY CLAMP ATRICLIP PRO・V® DEVICE © 2025 AtriCure, Inc. All rights reserved. 20
Slide 21: References and Abbreviations
References and Abbreviations Page Metric Reference Key Abbreviations Linz, D., Gawalko, M., Betz, K., Hendriks, J. M., Lip, G. Y., Vinter, N., Guo, Y. & Johnsen, S. (2024). Atrial fibrillation: Afib or Atrial Fibrillation 5 59 million people with Afib Worldwide AF epidemiology, screening and digital
Slide 22: Sources Tables
Sources Tables Treatment of Afib and LAAM Treatment of Afib and LAAM Advancing Guidelines for Clinical Practice Improving Access through Reimbursement Sources: January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland Jr, J. C., ... & Sources: In 2021, CMS moved CABG plus abl